ArticleWorld journal of surgery2026
The Impact of Obesity on Intraoperative, Oncological, and Postoperative Endpoints in Robotic Pancreaticoduodenectomy.
Article in World journal of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRobot-assisted pancreaticoduodenectomy (PD) has emerged as a surgical technique for an operation known for high postoperative morbidities. However, its impact on intraoperative and oncologic endpoints, and postoperative outcomes across higher body mass index (BMI) groups is not well established.
methodsWe conducted a retrospective analysis of 116 patients undergoing robot-assisted PD between 2018 and 2023, categorized by BMI into underweight/normal, overweight, and obese groups. Intraoperative (operative time, estimated blood loss), oncologic (lymph node yield, positive nodes), and postoperative (length of stay, composite adverse events) outcomes were compared using multivariate regression analysis.
resultsAmong 116 patients undergoing robot-assisted PD, 31.9% were underweight/normal, 45.7% overweight, and 22.1% were obese. Operative time (obese: 321.88 ± 77.87 min; overweight: 311.45 ± 71.21 min; normal: 304.16 ± 67.80 min; p = 0.63) and estimated blood loss (obese: 94.81 ± 81.57 mL; overweight: 115.00 ± 161.53 mL; normal: 104.3 ± 101.1 mL; p = 0.80) were similar across BMI groups. Lymph node yield did not significantly differ (obese: 24.81 ± 9.07; overweight: 21.83 ± 5.90; normal: 20.97 ± 5.06; p = 0.06). However, obese patients experienced a significantly higher rate of composite adverse events (CAE) (42.31%) than overweight (13.21%) and normal BMI groups (18.92%; p = 0.01). In the multivariable analysis, obesity was associated with increased odds of CAE (OR 3.50, 95% CI: 1.01-2.16). However, operative time, blood loss, lymph node yields, and length of stay did not have significant association with BMI.
conclusionHigher BMI was not associated with worse intraoperative and oncologic surgical quality with robot-assisted PD. However, obese patients were more likely to experience postoperative complications after robot-assisted PDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.